Are you looking for the legacy C3 device?

NCCN, ESMO and Cancer Australia recognize scalp cooling as standard of care.

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), European Society for Medical Oncology (ESMO), and Cancer Australia recognize scalp cooling as a treatment recommendation to reduce the incidence of chemotherapy-induced alopecia for breast cancer and ovarian cancer.

READ MORE >

The DigniCap Scalp Cooling System is FDA cleared to minimize hair loss in patients with solid tumors undergoing chemotherapy.

There are currently two models of The DigniCap Scalp Cooling System. Depending on your facility, you will either use the DigniCap C3 or DigniCap Delta. Both systems provide effective scalp cooling, but the machine and caps are different.

​CLINICIANS IN THE U.S.

DigniCap Delta Clinical Resources

​CLINICIANS OUTSIDE THE U.S.

DigniCap Delta Clinical Resources

DigniCap C3 Clinical Resources

In the film “Saving Identity” Dr. Hope Rugo of UCSF explains how scalp cooling reduces hair loss from chemo and the process from gaining approval for the first FDA cleared scalp cooling system in the US in 2015 to the launch of the new DigniCap Delta device in 2019.